Form 4: Vanda Pharmaceuticals CEO Receives 450,000 Shares of Restricted Stock

Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals, acquired 450,000 shares of common stock through a restricted stock unit award.

Summary

• Mihael Hristos Polymeropoulos, the President and CEO of Vanda Pharmaceuticals, received 450,000 shares of common stock on February 18, 2025.
• These shares are part of a time-based restricted stock unit (RSU) award.
• The RSU vests in four equal annual installments, starting on March 1, 2026, contingent upon continuous employment with Vanda Pharmaceuticals.
• Vested shares will be delivered on the first permissible trading day after each vesting date.
• Following this transaction, Polymeropoulos beneficially owns 2,321,730 shares of Vanda Pharmaceuticals.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, aligning management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The RSU award aligns the CEO's interests with the long-term performance of Vanda Pharmaceuticals.
• The vesting schedule encourages continued service and dedication from the CEO.

Risks

• The value of the restricted stock units is tied to the performance of Vanda Pharmaceuticals' stock, which can be volatile.
• The CEO must remain employed with the company to fully vest the RSU award.

Future Outlook

The CEO's continued employment is tied to the vesting of the RSU award, suggesting a commitment to the company's future.

Industry Context

Stock-based compensation is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Comparing the size of this RSU award to similar companies and executive roles would require further research into industry benchmarks for executive compensation.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also use stock options and restricted stock units as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the RSU award positively as it aligns the CEO's interests with the company's long-term success.
• Employees may see the award as a sign of confidence in the company's leadership.

Next Steps

• The CEO will need to remain employed with Vanda Pharmaceuticals to vest the RSU award.
• The company will likely report further details on executive compensation in its annual proxy statement.

Key Dates

Keywords

Vanda Pharmaceuticals, Mihael Polymeropoulos, restricted stock unit, RSU, beneficial ownership, Form 4, insider trading